Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis: Recent Updates

Opinion
Podcast

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS. [LISTEN TIME: 48 minutes]

To watch the video series component of this episode, click here.

2:09 Early intervention with high-efficacy DMTs in MS

4:26 Anti-CD20 antibodies in MS

8:26 B-cell therapies in MS

10:17 Choosing among different anti-CD20 therapies

13:50 Ublituximab and ULTIMATE I, II trials

22:22 Ublituximab in treatment naïve patients

23:16 Ublituximab in patients with highly active MS

25:45 Bridging the gap between immunology and clinical presentation of MS

28:43 Epstein Barr virus (EBV) and MS

44:46 Addressing patient concerns about EBV and MS

Related Videos
Michael Levy, MD, PhD
Michael Levy, MD, PhD
Tarun Singhal, MD, MBBS
Jaime Imitol, MD
Eoin P. Flanagan, MB, BCh
Eoin P. Flanagan, MB, BCh
© 2024 MJH Life Sciences

All rights reserved.